logo

COHANCE vs WOCKPHARMA: Stock Comparison

COHANCE LIFESCIENCES vs WOCKHARDTUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

WOCKHARDT is the larger company by market capitalisation. COHANCE LIFESCIENCES shows lower leverage and a higher net margin, while WOCKHARDT shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

COHANCE leads 3; WOCKPHARMA leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

COHANCEWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹17,906 Cr
₹30,126 Cr
P/E RatioWOCKPHARMA has the lower reading
163.99x
73.66x ✓
P/B RatioCOHANCE has the lower reading
4.46x ✓
6.1x
EPSWOCKPHARMA has the higher reading
₹-0.63
₹6.52 ✓
Book ValueContext only
₹105.44
₹325
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,126 Cr vs ₹17,906 Cr
P/E Ratio
WOCKPHARMA has a lower P/E
73.66x vs 163.99x
P/B Ratio
COHANCE has a lower P/B
4.46x vs 6.1x
EPS
WOCKPHARMA has higher earnings per share
₹6.52 vs ₹-0.63
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -26.3%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -89%
ROE
WOCKPHARMA has a higher ROE
3.77% vs 3.72%
ROCE
WOCKPHARMA has a higher ROCE
5.44% vs 4.26%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCOHANCEWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCOHANCEWOCKPHARMA
Live Price₹453.85₹1,855.5
Day Change-1.72%-1.16%
Volume4.12 L4.57 L
52-Week High₹903.4₹2,422.3
52-Week Low₹266.7₹1,086.7
Distance from 52W High-49.76%-23.4%

Valuation

MetricCOHANCEWOCKPHARMA
Market Cap₹17,906 Cr₹30,126 Cr
P/E Ratio163.99x73.66x
P/B Ratio4.46x6.1x
EPS₹-0.63₹6.52
Book Value₹105.44₹325
Dividend Yield0%0%

Growth

MetricCOHANCEWOCKPHARMA
Revenue Growth (TTM YoY)-26.3%26%
EPS Growth (TTM YoY)-89%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricCOHANCEWOCKPHARMA
ROE3.72%3.77%
ROCE4.26%5.44%
Net Margin7.9%3.3%
Operating Margin10.77%13.37%
Debt to Equity0.04x0.4x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricCOHANCEWOCKPHARMA
Promoter Holding0%49.08%
FII Holding7.71%▲ 1.21 pp7.22%▲ 0.13 pp
DII Holding18.86%▼ 1.23 pp9.24%▼ 1.72 pp
Public Holding15.95%▲ 0.03 pp34.44%▲ 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: COHANCE LIFESCIENCES and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.